Arena Pharmaceuticals Inc. is preparing to present its Phase 1 results in which the company tested ralinepag, a new drug developed for pulmonary arterial hypertension (PAH) patients.
The results will be presented at the American Thoracic Society Conference on May 23 in Washington, D.C.
"The Phase 1 clinical data supports our belief that ralinepag is a potential best-in-class oral prostacyclin therapy," Amit Munshi, Arena's president and CEO, said in a press release. "The acceptance of the scientific data presentation at ATS underscores the enthusiasm on the part of clinical investigators to continue to explore the novel profile of ralinepag."
The presentation, "Safety and Pharmacokinetics of Ralinepag (APD811), a Next-generation, Selective," will highlight “safety and pharmacokinetics of ralinepag in healthy volunteers.”
Arena Pharmaceuticals is working to develop and produce pharmaceutical drugs to help with therapeutic patients. The company has several additional clinical programs.
The company has collaborated with Eisai Co. Ltd. and Eisai Inc. (commercial stage), Axovant Sciences (Phase 2 candidate) and Boehringer Ingelheim International GmbH (preclinical candidate), according to the release.